Johnson & Johnson - Index

Johnson & Johnson - report - Index

���� ����������������
������������������������
���� �������
��������������
�����
���
����������������
�������������
�����
���
��������
�����
���
����������������
������������������������
������
����
������
���� ���� ���� ������������� �������������
����� ����������� ��� ��������� ������� ������� ������� ����� �����
��� �������� ��� ��������� ������� ������� ������� ������ �����
������� ������ �� ������� ������������� ������ ����� ����� ����� � ��
������� ��� �������� �������� ����� ����� ����� ������ ������
���� ��������� ���� �������� ������ ������ ������ ����� ������
������ ����� ��������� ������ ������ ������ ������ ���� ����
DORIBAX ® (doripenem for injection), a powerful antibacterial
for treatment of serious urinary tract and intra-abdominal
infections (also under review for treating hospital-acquired
pneumonia), and INVEGA ® (paliperidone) Extended-Release
Tablets, a once-daily atypical antipsychotic. In early 2008,
we launched IONSYS ™ (fentanyl iontophoretic transdermal
system), the first needle-free, patient-activated analgesic
system in Europe, and a new first-in-class HIV drug called
INTELENCE ™ (etravirine). Like PREZISTA ™ (darunavir), an
HIV medicine we introduced in 2006, INTELENCE ™ offers
new hope to many HIV patients who thought they were
running out of options.
In addition, five new medicines are currently under
regulatory review, including ustekinumab, a first-in-class
treatment for psoriasis with possible additional indications
for other autoimmune-related inflammatory conditions;
paliperidone palmitate, a long-acting injectable for treating
schizophrenia; and ceftobiprole, another powerful antibacterial.
We’ve also filed significant new indications for several
products, including PREZISTA ™ (darunavir) and CONCERTA ®
(methylphenidate HCl).
We expect to submit regulatory filings for between seven
and 10 new prescription drugs between 2008 and 2010 (see
pharmaceutical pipeline on page 27).
MEDICAL DEVICES AND DIAGNOSTICS Our medical device
and diagnostics (MD&D) franchises continue to comprise the
world’s largest medical technology business. We treat some
of the world’s most pervasive medical conditions with a more
comprehensive approach than any other company in this field.
In 2007, these businesses achieved sales of $21.7 billion, with
total growth of 7.2 percent. This was solid growth in light of a
significant decline in the market for drug-eluting stents (DES),
which took a toll on sales of the CYPHER ® Sirolimus-eluting
����
������
����
������������������
���
�������������
������������������������
���������������������������
�����������������
����
����
�����
����
�����������������������������������
Coronary Stent. Excluding the impact of the DES market
decline, we saw strong total growth of nearly 13 percent in our
MD&D franchises.
We enjoy strong competitive positions across our diverse
franchises, with more than 80 percent of MD&D sales coming
from businesses in the No. 1 or No. 2 market positions. Our
vision care business surpassed the $2 billion mark for the first
time in its history.
These businesses achieved a number of important
product launches and regulatory approvals, including U.S.
approval of the REALIZE ™ Adjustable Gastric Band, a device
for treatment of morbid obesity; the ANIMAS ® 2020 Insulin
Pump, the smallest full-featured insulin pump on the market;
and GENESEARCH ™ Breast Lymph Node (BLN) Assay, a novel
molecular diagnostic tool for detecting the spread of breast
cancer to the lymph nodes while the patient is undergoing
surgery. This assay helps breast cancer patients and their
doctors avoid the challenges of a second surgery to remove
cancerous lymph node tissue following results of a biopsy.
It was cited by TIME magazine as the second leading medical
breakthrough of 2007.
We are well-positioned in 2008 with a robust pipeline and
strategic development programs in orthopaedics, biosurgicals,
bariatric surgery, vision care, and other major categories.
OUR FORMULA FOR ENDURING GROWTH Last year was a
testament to the enduring strength of our operating model,
and to the commitment of our people in the face of challenge.
For decades, we have had a clear and consistent approach to
running our business that is both durable and adaptive
to change. Johnson & Johnson may be more than 120 years
old, but the entrepreneurial spirit of our decentralized
companies keeps them young and fresh in the way they
approach their markets.
���������� � � � ��� � �